Vall d’Hebron Barcelona Hospital Campus and IQVIA, the world’s largest Contract Research Organization (CRO), have renewed their preferential collaboration agreement (Prime Site Agreement), originally signed in 2018, which designates Vall d’Hebron as a preferred site for company-managed clinical trials. Vall d’Hebron was the first centre in Spain to join this international network and is currently the only public centre in the country that is part of it. The success of the collaboration over the years has enabled the agreement to be renewed and the campus to remain within this select group of globally chosen centres.

The renewed agreement, signed by IQVIA, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute (VHIR) and Vall d’Hebron Institute of Oncology (VHIO), will run for four years. During this period, both institutions commit to working together on the delivery of clinical trials within a framework of excellence, for the benefit of patients and all stakeholders involved. To this end, IQVIA will offer Vall d’Hebron company-managed clinical trials on a priority or preferential basis, though not exclusively.

The Prime Site Agreement defines governance structures, mutual expectations and operational principles aimed at facilitating the identification and efficient execution of clinical trials. In all cases, the full clinical, scientific and healthcare independence of the hospital and research centres will be preserved.

Two leading institutions in clinical trials

IQVIA is a leading global Contract Research Organization (CRO) and a provider of advanced analytics, technology solutions and clinical research services. It specialises in accelerating clinical development through AI-driven insights and real-world data, supporting pharmaceutical, biotechnology and medical device companies in more than 100 countries. Collaboration with Vall d’Hebron ensures that clinical trials are conducted in a benchmark, high-prestige centre in the field of clinical research.

For its part, Vall d’Hebron is a leading centre in clinical trials, both in terms of volume and complexity. The agreement with IQVIA enhances the centre’s visibility and positioning and enables professionals to gain knowledge and professional development. The main objective is to benefit patients, who, thanks to clinical trials, have more options to access therapies and treatments that were previously unavailable.